Raloxifene and Goserelin in Preventing Breast Cancer in Women With a Family History of Breast Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• High genetic risk of developing breast cancer defined as one or more of the following:
• * BRCA1 or BRCA2 germ-line mutation
• * First-degree relative of known BRCA1 or BRCA2 mutation carrier
• * Family with 4 or more relatives diagnosed with female or male breast cancer or ovarian cancer before the age of 60
• * Two first-degree relatives diagnosed with breast cancer before the age of 40
• * p53 germ-line mutation (classical Li-Fraumeni syndrome (LFS) only)
• * First-degree relative of a carrier in a family with classical LFS
• * Risk equivalent to any of the above confirmed by clinical geneticist
• No evidence of breast cancer by mammography
• * Suspicious lesions must be confirmed as non-malignant
• No prior breast cancer
• No prior prophylactic mastectomy
• No plan for alternative prevention measures within the next 12 months
• Hormone receptor status:
• * Not specified
• PATIENT CHARACTERISTICS:
• Age:
• 30 to 45
• Sex:
• Female
• Menopausal status:
• Premenopausal (follicle-stimulating hormone in premenopausal range if not menstruating)
• Performance status:
• Not specified
• Life expectancy:
• More than 10 years (excluding breast cancer risk)
• Hematopoietic:
• Not specified
• Hepatic:
• Adequate liver function
• Renal:
• Adequate renal function
• Cardiovascular:
• No prior deep vein thrombosis
• Pulmonary:
• No prior pulmonary embolism
• Other:
• Not pregnant
• Fertile patients must use effective nonhormonal contraception
• No psychological disorder that would preclude study compliance
• No prior malignancy within the past 5 years except curatively treated nonmelanoma skin cancer or cervical cancer
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• Not specified
• Chemotherapy:
• Not specified
• Endocrine therapy:
• No concurrent hormonal therapy (e.g., oral contraception or hormone replacement therapy)
• Radiotherapy:
• Not specified
• Surgery:
• See Disease Characteristics
• Other:
• At least 30 days or 5 half-lives since prior investigational drugs
• No concurrent anticoagulants